GenKyoTex Moves NOX Inhibitor To Phase I; Starts Partner Hunt
BioWorld International Correspondent
LONDON – GenKyoTex has begun initial prospecting for commercialization partners as its first-in-class dual NOX inhibitor, GKT137831, enters Phase I trials, and academic collaborators deliver further evidence of the drug's therapeutic effect in models of diabetic nephropathy.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST